Jarmila Kruseova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jarmila Kruseova has a total of 298 co-authors. Here are the top co-authors by number of shared publications:
- Tomas Kepak
International Clinical Research Center, St. Anne’s University Hospital Brno, Brno, Czech Republic
7 shared publications - Andreas Ranft
Pediatrics III, University Hospital Essen, West German Cancer Center, NCT West, Essen, Germany
5 shared publications - Julianne Byrne
Boyne Research Institute
5 shared publications - Marry M. van Den Heuvel-Eibrink
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
5 shared publications - Desiree Grabow
Deutsches Kinderkrebsregister (DKKR), Abteilung Epidemiologie von Krebs im Kindesalter, Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland
4 shared publications - Tomas Eckschlager
Charles University and Motol University Hospital
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (10)
Risk factors for subsequent thyroid neoplasm development in childhood cancer survivors
Subsequent thyroid carcinomas (STCs) are common after childhood cancer treatment and have well-described risk factors, whereas information on subsequent thyroid adenomas (STAs) remains limited. This study compared treatment-related risk factors for STCs and STAs, assessed their associations with other subsequent neoplasms, and evaluated the incidence of STCs relative to that in the age-matched national general population. The study cohort included 4,348 childhood cancer survivors treated between 1975 and 2020; 48% were female, 23% had lymphomas, and 77% had solid tumors. STCs occurred in 44 survivors (59% female), and STAs occurred in 23 (65% female). Compared with the national general population, the risk of STCs was 7.6-fold higher in females and 23.6-fold higher in males. The median age at diagnosis was lower for STCs (25.8 vs 29.8 years). Hodgkin lymphoma was the most frequent primary cancer in both groups (48% vs 57%). The median age at first cancer diagnosis was similar between the groups (9.8 vs 9.4 years). Neck radiotherapy was a major risk factor in both groups (59% vs 83%). Additional subsequent malignant neoplasms occurred in 14% of patients with STCs and 13% of patients with STAs, whereas subsequent benign neoplasms occurred in 20% and 26%, respectively. The incidence of subsequent benign neoplasms was higher in patients with STCs than in patients with other first subsequent malignant neoplasms (P < 0.05). STCs predominated over STAs (66%). Shared risk factors included neck radiotherapy and Hodgkin lymphoma. STCs were diagnosed at a younger age. The frequent occurrence of additional subsequent neoplasms highlights the need for long-term surveillance.
- 1 October 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (10)
Open AccessRisk factors for subsequent thyroid neoplasm development in childhood cancer survivors
Subsequent thyroid carcinomas (STCs) are common after childhood cancer treatment and have well-described risk factors, whereas information on subsequent thyroid adenomas (STAs) remains limited. This study compared treatment-related risk factors for STCs and STAs, assessed their associations with other subsequent neoplasms, and evaluated the incidence of STCs relative to that in the age-matched national general population. The study cohort included 4,348 childhood cancer survivors treated between 1975 and 2020; 48% were female, 23% had lymphomas, and 77% had solid tumors. STCs occurred in 44 survivors (59% female), and STAs occurred in 23 (65% female). Compared with the national general population, the risk of STCs was 7.6-fold higher in females and 23.6-fold higher in males. The median age at diagnosis was lower for STCs (25.8 vs 29.8 years). Hodgkin lymphoma was the most frequent primary cancer in both groups (48% vs 57%). The median age at first cancer diagnosis was similar between the groups (9.8 vs 9.4 years). Neck radiotherapy was a major risk factor in both groups (59% vs 83%). Additional subsequent malignant neoplasms occurred in 14% of patients with STCs and 13% of patients with STAs, whereas subsequent benign neoplasms occurred in 20% and 26%, respectively. The incidence of subsequent benign neoplasms was higher in patients with STCs than in patients with other first subsequent malignant neoplasms (P < 0.05). STCs predominated over STAs (66%). Shared risk factors included neck radiotherapy and Hodgkin lymphoma. STCs were diagnosed at a younger age. The frequent occurrence of additional subsequent neoplasms highlights the need for long-term surveillance.
- Open Access
- 14 February 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 101, 103019
Does motherhood increase the risk of developing subsequent malignant neoplasms after childhood cancer treatment?
- 14 February 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 101, 103019
Open AccessDoes motherhood increase the risk of developing subsequent malignant neoplasms after childhood cancer treatment?
- Open Access
- 16 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Sedentary behavior and physical activity in survivors of childhood hodgkin lymphoma: a cross-sectional study
Hodgkin lymphoma (HL) is one of the most common cancers during adolescence. Advances in treatment have achieved survival rates exceeding 90%. However, long-term treatment-related sequelae, including cardiovascular disease and metabolic syndrome, significantly affect the quality of life of survivors. Physical activity (PA) is considered a key strategy to mitigate these risks. Current studies predominantly rely on subjective assessments of movement behavior, which may lack accuracy. This cross-sectional study aims to use device-based monitoring to characterize levels of sedentary behavior and physical activity in survivors of childhood-diagnosed HL. Specific objectives were to evaluate these behaviors across age and gender groups and to assess compliance with physical activity guidelines for the adult population. The study involved 51 participants (59% female), with a median age of 25 years, a median age at diagnosis of 16 years, and a median time since diagnosis of 11 years. PA and sedentary behavior (SB) were measured over seven days using the Axivity AX3 accelerometer with a 24-hour wear protocol. Movement behavior was categorized into SB, light PA (LPA), moderate PA (MPA), and vigorous PA (VPA). Group differences in movement behaviors were examined using non-parametric tests, and results are presented as medians with interquartile ranges. Participants had a median daily time of 704.8 min in SB (IQR 127.9), 181.2 min in LPA (IQR 81.3), 110.2 min in MPA (IQR 68.8), and 2.8 min in VPA (IQR 2.8). Combined moderate-to-vigorous physical activity (MVPA) accounted for a median of 115 min per day (IQR 69.8). Significant differences in LPA were observed: men spent less time in LPA compared to women ( p = 0.032), and younger participants spent less time in LPA compared to older participants ( p = 0.006). While 100% of participants met the WHO-recommended threshold of > 150 min of MPA per week, only 14% met the guideline of > 75 min of VPA per week. Our study indicates that survivors diagnosed with childhood HL can achieve the levels of MVPA recommended by current adult PA guidelines, despite undergoing chemotherapy and radiotherapy. Additionally, significant differences in low-intensity PA were identified: men and younger participants spent less time in LPA compared to women and older participants, respectively. These findings highlight the importance of monitoring movement behaviors in long-term follow-up care to identify survivors with insufficient physical activity and excessive sedentary behavior and to implement targeted interventions to reduce long-term cardiovascular and metabolic risk. Given the cross-sectional design, causal relationships and changes in physical activity behavior over time cannot be inferred.
- 16 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessSedentary behavior and physical activity in survivors of childhood hodgkin lymphoma: a cross-sectional study
Hodgkin lymphoma (HL) is one of the most common cancers during adolescence. Advances in treatment have achieved survival rates exceeding 90%. However, long-term treatment-related sequelae, including cardiovascular disease and metabolic syndrome, significantly affect the quality of life of survivors. Physical activity (PA) is considered a key strategy to mitigate these risks. Current studies predominantly rely on subjective assessments of movement behavior, which may lack accuracy. This cross-sectional study aims to use device-based monitoring to characterize levels of sedentary behavior and physical activity in survivors of childhood-diagnosed HL. Specific objectives were to evaluate these behaviors across age and gender groups and to assess compliance with physical activity guidelines for the adult population. The study involved 51 participants (59% female), with a median age of 25 years, a median age at diagnosis of 16 years, and a median time since diagnosis of 11 years. PA and sedentary behavior (SB) were measured over seven days using the Axivity AX3 accelerometer with a 24-hour wear protocol. Movement behavior was categorized into SB, light PA (LPA), moderate PA (MPA), and vigorous PA (VPA). Group differences in movement behaviors were examined using non-parametric tests, and results are presented as medians with interquartile ranges. Participants had a median daily time of 704.8 min in SB (IQR 127.9), 181.2 min in LPA (IQR 81.3), 110.2 min in MPA (IQR 68.8), and 2.8 min in VPA (IQR 2.8). Combined moderate-to-vigorous physical activity (MVPA) accounted for a median of 115 min per day (IQR 69.8). Significant differences in LPA were observed: men spent less time in LPA compared to women ( p = 0.032), and younger participants spent less time in LPA compared to older participants ( p = 0.006). While 100% of participants met the WHO-recommended threshold of > 150 min of MPA per week, only 14% met the guideline of > 75 min of VPA per week. Our study indicates that survivors diagnosed with childhood HL can achieve the levels of MVPA recommended by current adult PA guidelines, despite undergoing chemotherapy and radiotherapy. Additionally, significant differences in low-intensity PA were identified: men and younger participants spent less time in LPA compared to women and older participants, respectively. These findings highlight the importance of monitoring movement behaviors in long-term follow-up care to identify survivors with insufficient physical activity and excessive sedentary behavior and to implement targeted interventions to reduce long-term cardiovascular and metabolic risk. Given the cross-sectional design, causal relationships and changes in physical activity behavior over time cannot be inferred.
- 20 May 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2402534
Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group
PURPOSE: Childhood, adolescent, and young adult (CAYA) survivors of cancer are at risk of nephrotoxicity. Surveillance guidelines are important for timely diagnosis and treatment of these survivors, which could slow the progression to higher stages of kidney dysfunction. METHODS: The International Late Effects of Childhood Cancer Guideline Harmonization Group established a multidisciplinary panel of 34 experts from 11 countries. The panel performed systematic literature reviews for articles published between 1990 and June 2023, graded the evidence using Grading of Recommendations Assessment, Development, and Evaluation methodology, and formulated recommendations based on evidence, clinical judgment, and consideration of benefits and harms of surveillance. Recommendations were critically appraised by two independent external experts and patient representatives. RESULTS: Glomerular dysfunction surveillance is recommended every 2-5 years for survivors treated with ifosfamide, cisplatin, abdominal radiotherapy, total body irradiation, or nephrectomy and is reasonable after carboplatin treatment. We recommend screening for glomerular dysfunction using an estimated glomerular filtration rate (eGFR) equation that includes serum creatinine, preferably combined with serum cystatin C if available. Tubular dysfunction surveillance is recommended once at entry into long-term follow-up and with follow-up as clinically indicated for survivors treated with ifosfamide and is reasonable after cisplatin treatment. CONCLUSION: These recommendations inform routine, uniform long-term follow-up care for CAYA survivors of cancer at risk of nephrotoxicity.
- 20 May 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2402534
Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group
PURPOSE: Childhood, adolescent, and young adult (CAYA) survivors of cancer are at risk of nephrotoxicity. Surveillance guidelines are important for timely diagnosis and treatment of these survivors, which could slow the progression to higher stages of kidney dysfunction. METHODS: The International Late Effects of Childhood Cancer Guideline Harmonization Group established a multidisciplinary panel of 34 experts from 11 countries. The panel performed systematic literature reviews for articles published between 1990 and June 2023, graded the evidence using Grading of Recommendations Assessment, Development, and Evaluation methodology, and formulated recommendations based on evidence, clinical judgment, and consideration of benefits and harms of surveillance. Recommendations were critically appraised by two independent external experts and patient representatives. RESULTS: Glomerular dysfunction surveillance is recommended every 2-5 years for survivors treated with ifosfamide, cisplatin, abdominal radiotherapy, total body irradiation, or nephrectomy and is reasonable after carboplatin treatment. We recommend screening for glomerular dysfunction using an estimated glomerular filtration rate (eGFR) equation that includes serum creatinine, preferably combined with serum cystatin C if available. Tubular dysfunction surveillance is recommended once at entry into long-term follow-up and with follow-up as clinically indicated for survivors treated with ifosfamide and is reasonable after cisplatin treatment. CONCLUSION: These recommendations inform routine, uniform long-term follow-up care for CAYA survivors of cancer at risk of nephrotoxicity.
- Open Access
Implementation of the Short-Form 36 (SF-36) in childhood cancer survivors: An analysis on measurement properties across 5 European countries
Purpose The Short Form-36 (SF-36) is widely used in many research contexts and cultures to assess health-related quality of life (HRQOL). We investigated the measurement properties of the SF-36 in a large cohort study among childhood cancer survivors living in 5 European countries. Methods The PanCareLIFE project includes adult survivors of childhood cancer living in the Czech Republic, France, Germany, The Netherlands, and Switzerland. We invited 19,268 survivors aged >18 years, and 10,077 (53%) returned questionnaires. Of these, 9,871 (98%) were included in the analyses. We assessed HRQOL with the SF-36 version 1 (V1) or version 2 (V2) and investigated its performance. We analysed data completeness, floor and ceiling effects, item-internal consistency, item-discriminant validity, reliability, and scaling assumptions focusing on country-and version-specific differences. Results Data completeness was high but differed between countries (90% in the Czech Republic to 96% in France). Floor effects were negligible, but ceiling effects in 5 out of 8 SF-36 scales were present (50-70%). V2 had slightly fewer ceiling effects than V1 in 2 scales. Item-internal consistency, item-discriminant validity, and reliability were good. Scaling assumptions were met, with 4 scales representing strong mental health content, and the other 4 representing strong physical health content. Conclusion The SF-36 (V1 and V2) provided robust measurement properties among childhood cancer survivors, and differences in study design across the 5 European countries did not affect measurement properties. Researchers need to take into account that ceiling effects exist which might limit sensitivity among participants who fared particularly well. PLAIN ENGLISH SUMMARY This study investigated how well the Short Form-36 (SF-36), a commonly used tool for assessing health-related quality of life, performs in childhood cancer survivors from five different European countries. We looked at the amount of survivors answering to all of the SF-36 questions, how many indicated the most positive or the most negative answer category, whether the questions were consistent within the different aspects of the questionnaire and how consistent and dependable it measured quality of life in the survivors. We found that overall, the SF-36 measured health-related quality of life well in all the countries. This is reassuring for researchers considering its use in studies involving multiple centers across Europe.
Open AccessImplementation of the Short-Form 36 (SF-36) in childhood cancer survivors: An analysis on measurement properties across 5 European countries
Purpose The Short Form-36 (SF-36) is widely used in many research contexts and cultures to assess health-related quality of life (HRQOL). We investigated the measurement properties of the SF-36 in a large cohort study among childhood cancer survivors living in 5 European countries. Methods The PanCareLIFE project includes adult survivors of childhood cancer living in the Czech Republic, France, Germany, The Netherlands, and Switzerland. We invited 19,268 survivors aged >18 years, and 10,077 (53%) returned questionnaires. Of these, 9,871 (98%) were included in the analyses. We assessed HRQOL with the SF-36 version 1 (V1) or version 2 (V2) and investigated its performance. We analysed data completeness, floor and ceiling effects, item-internal consistency, item-discriminant validity, reliability, and scaling assumptions focusing on country-and version-specific differences. Results Data completeness was high but differed between countries (90% in the Czech Republic to 96% in France). Floor effects were negligible, but ceiling effects in 5 out of 8 SF-36 scales were present (50-70%). V2 had slightly fewer ceiling effects than V1 in 2 scales. Item-internal consistency, item-discriminant validity, and reliability were good. Scaling assumptions were met, with 4 scales representing strong mental health content, and the other 4 representing strong physical health content. Conclusion The SF-36 (V1 and V2) provided robust measurement properties among childhood cancer survivors, and differences in study design across the 5 European countries did not affect measurement properties. Researchers need to take into account that ceiling effects exist which might limit sensitivity among participants who fared particularly well. PLAIN ENGLISH SUMMARY This study investigated how well the Short Form-36 (SF-36), a commonly used tool for assessing health-related quality of life, performs in childhood cancer survivors from five different European countries. We looked at the amount of survivors answering to all of the SF-36 questions, how many indicated the most positive or the most negative answer category, whether the questions were consistent within the different aspects of the questionnaire and how consistent and dependable it measured quality of life in the survivors. We found that overall, the SF-36 measured health-related quality of life well in all the countries. This is reassuring for researchers considering its use in studies involving multiple centers across Europe.
- 16 October 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (24) , 5057-5068
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Purpose: The phase III, open-label, prospective, multicenter, randomized Ewing 2008R1 trial (EudraCT2008-003658-13) was conducted in 12 countries to evaluate the effect of zoledronic acid (ZOL) maintenance therapy compared with no add-on regarding event-free survival (EFS, primary endpoint) and overall survival (OS) in standard-risk Ewing sarcoma (EWS).Patients and Methods: Eligible patients had localized EWS with either good histologic response to induction chemotherapy and/or small tumors (<200 mL). Patients received six cycles of VIDE induction and eight cycles of VAI (male) or eight cycles of VAC (female) consolidation. ZOL treatment started parallel to the sixth consolidation cycle. Randomization was stratified by tumor site (pelvis/other). The two-sided adaptive inverse–normal four-stage design (planned sample size 448 patients, significance level 5%, power 80%) was changed after the first interim analysis using the Müller–Schäfer method.Results: Between April 2010 and November 2018, 284 patients were randomized (142 ZOL/142 no add-on). With a median follow-up of 3.9 years, EFS was not significantly different between ZOL and no add-on group in the adaptive design (HR, 0.74; 95% CI, 0.43–1.28, P = 0.27, intention-to-treat). Three-year EFS rates were 84.0% (95% CI, 77.7%–90.8%) for ZOL vs. 81.7% (95% CI, 75.2%–88.8%) for no add-on. Results were similar in the per-protocol collective. OS was not different between groups. The 3-year OS was 92.8% (95% CI, 88.4%–97.5%) for ZOL and 94.6% (95% CI, 90.9%–98.6%) for no add-on. Noticeable more renal, neurologic, and gastrointestinal toxicities were observed for ZOL (P < 0.05). Severe renal toxicities occurred more often in the ZOL arm (P = 0.003).Conclusions: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.
- 16 October 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (24) , 5057-5068
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Purpose: The phase III, open-label, prospective, multicenter, randomized Ewing 2008R1 trial (EudraCT2008-003658-13) was conducted in 12 countries to evaluate the effect of zoledronic acid (ZOL) maintenance therapy compared with no add-on regarding event-free survival (EFS, primary endpoint) and overall survival (OS) in standard-risk Ewing sarcoma (EWS).Patients and Methods: Eligible patients had localized EWS with either good histologic response to induction chemotherapy and/or small tumors (<200 mL). Patients received six cycles of VIDE induction and eight cycles of VAI (male) or eight cycles of VAC (female) consolidation. ZOL treatment started parallel to the sixth consolidation cycle. Randomization was stratified by tumor site (pelvis/other). The two-sided adaptive inverse–normal four-stage design (planned sample size 448 patients, significance level 5%, power 80%) was changed after the first interim analysis using the Müller–Schäfer method.Results: Between April 2010 and November 2018, 284 patients were randomized (142 ZOL/142 no add-on). With a median follow-up of 3.9 years, EFS was not significantly different between ZOL and no add-on group in the adaptive design (HR, 0.74; 95% CI, 0.43–1.28, P = 0.27, intention-to-treat). Three-year EFS rates were 84.0% (95% CI, 77.7%–90.8%) for ZOL vs. 81.7% (95% CI, 75.2%–88.8%) for no add-on. Results were similar in the per-protocol collective. OS was not different between groups. The 3-year OS was 92.8% (95% CI, 88.4%–97.5%) for ZOL and 94.6% (95% CI, 90.9%–98.6%) for no add-on. Noticeable more renal, neurologic, and gastrointestinal toxicities were observed for ZOL (P < 0.05). Severe renal toxicities occurred more often in the ZOL arm (P = 0.003).Conclusions: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.
- Open Access
Auditory Complications among Childhood Cancer Survivors and Health-related Quality of Life: A PanCareLIFE study
Auditory complications are potential side effects from childhood cancer treatment. Yet, limited evidence exists about the impact of auditory complications—particularly tinnitus—on health-related quality of life (HRQoL) among childhood cancer survivors (CCS). We determined the prevalence of hearing loss and tinnitus in the large European PanCareLIFE cohort of CCS and examined its effect on HRQoL. We included CCS from four European countries who were diagnosed at age ≤ 18 years; survived ≥ 5 years; and aged 25–44 years at study. We assessed HRQoL (Short Form 36), hearing loss, and tinnitus using questionnaires. We used multivariable linear regression to examine associations between these two auditory complications and HRQoL adjusting for socio-demographic and clinical factors. Our study population consisted of 6,318 CCS (53% female; median age at cancer diagnosis 9 years interquartile range [IQR] 5–13 years) with median age at survey of 31 years (IQR 28–35 years). Prevalence was 7.5% (confidence interval [CI]: 6.9–8.2) for hearing loss and 7.6% (CI: 6.4–9.0) for tinnitus. CCS with hearing loss had impaired physical (coefficient [coef.] - 4.3, CI: -7.0 to -1.6) and mental (coef. -3.2, CI: -5.5 to -0.8) HRQoL when compared with CCS with normal hearing. Tinnitus was also associated with impaired physical (coef. -8.2, CI: -11.8 to -4.7) and mental (coef. -5.9, CI: -8.8 to -3.1) HRQoL. We observed the lowest HRQoL among CCS with both hearing loss and tinnitus. Our findings indicate timely treatment of hearing loss and tinnitus may contribute to quality of life of survivors.
Open AccessAuditory Complications among Childhood Cancer Survivors and Health-related Quality of Life: A PanCareLIFE study
Auditory complications are potential side effects from childhood cancer treatment. Yet, limited evidence exists about the impact of auditory complications—particularly tinnitus—on health-related quality of life (HRQoL) among childhood cancer survivors (CCS). We determined the prevalence of hearing loss and tinnitus in the large European PanCareLIFE cohort of CCS and examined its effect on HRQoL. We included CCS from four European countries who were diagnosed at age ≤ 18 years; survived ≥ 5 years; and aged 25–44 years at study. We assessed HRQoL (Short Form 36), hearing loss, and tinnitus using questionnaires. We used multivariable linear regression to examine associations between these two auditory complications and HRQoL adjusting for socio-demographic and clinical factors. Our study population consisted of 6,318 CCS (53% female; median age at cancer diagnosis 9 years interquartile range [IQR] 5–13 years) with median age at survey of 31 years (IQR 28–35 years). Prevalence was 7.5% (confidence interval [CI]: 6.9–8.2) for hearing loss and 7.6% (CI: 6.4–9.0) for tinnitus. CCS with hearing loss had impaired physical (coefficient [coef.] - 4.3, CI: -7.0 to -1.6) and mental (coef. -3.2, CI: -5.5 to -0.8) HRQoL when compared with CCS with normal hearing. Tinnitus was also associated with impaired physical (coef. -8.2, CI: -11.8 to -4.7) and mental (coef. -5.9, CI: -8.8 to -3.1) HRQoL. We observed the lowest HRQoL among CCS with both hearing loss and tinnitus. Our findings indicate timely treatment of hearing loss and tinnitus may contribute to quality of life of survivors.
- 24 December 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 161 (1) , 155-163
Evaluation of the growth rates and related prognostic factors in radiation-induced meningiomas
Purpose Literature dedicated to growth patterns and growth rate influencing factors of radiation-induced meningiomas (RIMs) is limited. To deliver new insights into the topic, a volumetric growth analysis of RIMs was performed. Methods This single-center, retrospective cohort study included patients diagnosed with intracranial meningioma who received radiation treatment at least > 5 years before the RIM diagnosis. Volumetric analysis of individual RIMs was performed using 3D volumetry at the time of RIM diagnosis and during follow-up. RIM growth was determined by calculating absolute (AGR), and relative (RGR) growth rates. Prognostic factors associated with RIM growth were evaluated. Results A total of 26 patients with 33 meningiomas were enrolled in the study and radiologically/clinically followed up during a median duration of 5.6 years (IQR 3.9–8.8 years). Median AGR was 0.19 cm3 per year and the median RGR was 34.5% per year. Surgically managed RIMs were more likely fast-growing compared to observed ones based on the AGR (p < 0.002). The recurrence rate after total resection was 14.3%. Younger age at RIM diagnosis was associated with higher tumor growth (RGR ≥ 30%, p = 0.040). A significant correlation was found between the length of latency period and the RGR (p = 0.005). Conclusion To diagnose RIM as early as possible comprehensive MRI surveillance is required. Younger patients with shorter latency periods may profit from shortened MRI intervals, with further management being dependent on the growth rate and eventual symptomatology.
- 24 December 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 161 (1) , 155-163
Evaluation of the growth rates and related prognostic factors in radiation-induced meningiomas
Purpose Literature dedicated to growth patterns and growth rate influencing factors of radiation-induced meningiomas (RIMs) is limited. To deliver new insights into the topic, a volumetric growth analysis of RIMs was performed. Methods This single-center, retrospective cohort study included patients diagnosed with intracranial meningioma who received radiation treatment at least > 5 years before the RIM diagnosis. Volumetric analysis of individual RIMs was performed using 3D volumetry at the time of RIM diagnosis and during follow-up. RIM growth was determined by calculating absolute (AGR), and relative (RGR) growth rates. Prognostic factors associated with RIM growth were evaluated. Results A total of 26 patients with 33 meningiomas were enrolled in the study and radiologically/clinically followed up during a median duration of 5.6 years (IQR 3.9–8.8 years). Median AGR was 0.19 cm3 per year and the median RGR was 34.5% per year. Surgically managed RIMs were more likely fast-growing compared to observed ones based on the AGR (p < 0.002). The recurrence rate after total resection was 14.3%. Younger age at RIM diagnosis was associated with higher tumor growth (RGR ≥ 30%, p = 0.040). A significant correlation was found between the length of latency period and the RGR (p = 0.005). Conclusion To diagnose RIM as early as possible comprehensive MRI surveillance is required. Younger patients with shorter latency periods may profit from shortened MRI intervals, with further management being dependent on the growth rate and eventual symptomatology.
- Open Access
- 15 August 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (8) , 5748-5762
The Use of Assisted Reproductive Technology by European Childhood Cancer Survivors
CCS often wish to have biological children yet harbour concerns about fertility impairment, pregnancy risks and the general health risks of prospective offspring. To clarify these concerns, health outcomes in survivor offspring born following ART (n = 74, 4.5%) or after spontaneous conception (n = 1585) were assessed in our European offspring study by descriptive and bivariate analysis. Outcomes were compared to a sibling offspring cohort (n = 387) in a 4:1 matched-pair analysis (n = 1681). (i) Survivors were more likely to employ ART than their siblings (4.5% vs. 3.7%, p = 0.501). Successful pregnancies were achieved after a median of one cycle with, most commonly, intracytoplasmic sperm injection (ICSI) using non-cryopreserved oocytes/sperm. (ii) Multiple-sibling births (p < 0.001, 29.7% vs. 2.5%), low birth weight (p < 0.001; OR = 3.035, 95%-CI = 1.615–5.706), and preterm birth (p < 0.001; OR = 2.499, 95%-CI = 1.401–4.459) occurred significantly more often in survivor offspring following ART utilisation than in spontaneously conceived children. ART did not increase the prevalence of childhood cancer, congenital malformations or heart defects. (iii) These outcomes had similar prevalences in the sibling population. In our explorative study, we could not detect an influence on health outcomes when known confounders, such as multiple births, were taken into account.
- 15 August 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (8) , 5748-5762
Open AccessThe Use of Assisted Reproductive Technology by European Childhood Cancer Survivors
CCS often wish to have biological children yet harbour concerns about fertility impairment, pregnancy risks and the general health risks of prospective offspring. To clarify these concerns, health outcomes in survivor offspring born following ART (n = 74, 4.5%) or after spontaneous conception (n = 1585) were assessed in our European offspring study by descriptive and bivariate analysis. Outcomes were compared to a sibling offspring cohort (n = 387) in a 4:1 matched-pair analysis (n = 1681). (i) Survivors were more likely to employ ART than their siblings (4.5% vs. 3.7%, p = 0.501). Successful pregnancies were achieved after a median of one cycle with, most commonly, intracytoplasmic sperm injection (ICSI) using non-cryopreserved oocytes/sperm. (ii) Multiple-sibling births (p < 0.001, 29.7% vs. 2.5%), low birth weight (p < 0.001; OR = 3.035, 95%-CI = 1.615–5.706), and preterm birth (p < 0.001; OR = 2.499, 95%-CI = 1.401–4.459) occurred significantly more often in survivor offspring following ART utilisation than in spontaneously conceived children. ART did not increase the prevalence of childhood cancer, congenital malformations or heart defects. (iii) These outcomes had similar prevalences in the sibling population. In our explorative study, we could not detect an influence on health outcomes when known confounders, such as multiple births, were taken into account.
- 20 July 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (21) , 2307-2320
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma
PURPOSE: Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS). METHODS: Phase III, open-label, prospective, multicenter, randomized controlled clinical trial. Eligible patients had disseminated EWS with metastases to bone and/or other sites, excluding patients with only pulmonary metastases. Patients received six cycles of vincristine, ifosfamide, doxorubicin, and etoposide induction and eight cycles of vincristine, actinomycin D, and cyclophosphamide consolidation therapy. Patients were randomly assigned to receive additional TreoMel-HDT or no further treatment (control). The random assignment was stratified by number of bone metastases (1, 2-5, and > 5). The one-sided adaptive-inverse-normal-4-stage-design was changed after the first interim analysis via Müller-Schäfer method. RESULTS: Between 2009 and 2018, 109 patients were randomly assigned, and 55 received TreoMel-HDT. With a median follow-up of 3.3 years, there was no significant difference in EFS between TreoMel-HDT and control in the adaptive design (hazard ratio [HR] 0.85; 95% CI, 0.55 to 1.32, intention-to-treat). Three-year EFS was 20.9% (95% CI, 11.5 to 37.9) in TreoMel-HDT and 19.2% (95% CI, 10.8 to 34.4) in control patients. The results were similar in the per-protocol collective. Males treated with TreoMel-HDT had better EFS compared with controls: median 1.0 years (95% CI, 0.8 to 2.2) versus 0.6 years (95% CI, 0.5 to 0.9); P = .035; HR 0.52 (0.28 to 0.97). Patients age < 14 years benefited from TreoMel-HDT with a 3-years EFS of 39.3% (95% CI, 20.4 to 75.8%) versus 9% (95% CI, 2.4 to 34); P = .016; HR 0.40 (0.19 to 0.87). These effects were similar in the per-protocol collective. This observation is supported by comparable results from the nonrandomized trial EE99R3. CONCLUSION: In patients with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients. TreoMel-HDT may be of benefit for children age < 14 years.
- 20 July 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (21) , 2307-2320
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma
PURPOSE: Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS). METHODS: Phase III, open-label, prospective, multicenter, randomized controlled clinical trial. Eligible patients had disseminated EWS with metastases to bone and/or other sites, excluding patients with only pulmonary metastases. Patients received six cycles of vincristine, ifosfamide, doxorubicin, and etoposide induction and eight cycles of vincristine, actinomycin D, and cyclophosphamide consolidation therapy. Patients were randomly assigned to receive additional TreoMel-HDT or no further treatment (control). The random assignment was stratified by number of bone metastases (1, 2-5, and > 5). The one-sided adaptive-inverse-normal-4-stage-design was changed after the first interim analysis via Müller-Schäfer method. RESULTS: Between 2009 and 2018, 109 patients were randomly assigned, and 55 received TreoMel-HDT. With a median follow-up of 3.3 years, there was no significant difference in EFS between TreoMel-HDT and control in the adaptive design (hazard ratio [HR] 0.85; 95% CI, 0.55 to 1.32, intention-to-treat). Three-year EFS was 20.9% (95% CI, 11.5 to 37.9) in TreoMel-HDT and 19.2% (95% CI, 10.8 to 34.4) in control patients. The results were similar in the per-protocol collective. Males treated with TreoMel-HDT had better EFS compared with controls: median 1.0 years (95% CI, 0.8 to 2.2) versus 0.6 years (95% CI, 0.5 to 0.9); P = .035; HR 0.52 (0.28 to 0.97). Patients age < 14 years benefited from TreoMel-HDT with a 3-years EFS of 39.3% (95% CI, 20.4 to 75.8%) versus 9% (95% CI, 2.4 to 34); P = .016; HR 0.40 (0.19 to 0.87). These effects were similar in the per-protocol collective. This observation is supported by comparable results from the nonrandomized trial EE99R3. CONCLUSION: In patients with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients. TreoMel-HDT may be of benefit for children age < 14 years.